Whether you need systematic reviews for a Health Technology Appraisal or to inform product positioning or clinical trial design, epidemica provides high quality research identification, selection, risk of bias assessment & considered interpretation by experienced professionalsVIEW MORE
Whether producing network diagrams, Forest plots, Funnel plots or further graphical outputs from statistical packages, epidemica strives to help you better visualise, interrogate and interpret the available evidence regarding data availability and gaps, heterogeneity, publication bias or small study effects before you start your meta-analysisVIEW MORE
Be certain that the comparators you choose for your phase II and III clinical trials will enable your product to be compared to the network of existing research evidence in your target populationVIEW MORE
Need to identify and justify the use of utilities or mapping algorithms for health states in an economic model? According to NICE, SMC, PBAC and/or CADTH requirements? epidemica is engaged in methods research in the identification of utilities and as an invited member of the Delphi panel for the Reporting Checklist for Mapping Studies Working GroupVIEW MORE
There are published recommendations on how to critically review and interpret network meta-analyses when preparing network meta-analysis manuscripts for submissions to peer-reviewed journals. epidemica can help you implement these.VIEW MORE
epidemica provides systematic reviews to expedite eu market access of innovative medicines
We are a networked team of expert professionals with in-depth experience across both the pharmaceutical industry and HEOR consulting. We conduct systematic reviews and meta-analyses that meet Health Technology Assessment methodological requirements.
Our first-hand experience of randomised controlled trials and economic evaluations as primary research enables us to better critique clinical and health economic literature during secondary research.
epidemica offers a process borne from years of experience, designed to deliver quality output within a specified budget and timescale, starting from the brief and protocol, through to final data presentation.
We offer a portfolio of inter-related disciplines, the combination of which provides in-depth assessment and full exploration of your decision problem.
Our services include:
Our key strengths lie in the therapeutic areas of oncology (breast cancer in (neo)-adjuvant, metastatic first line, metastatic second or later line, HER2+/HER2- settings, TNBC, gastric and oesophageal cancer, SCCHN and renal cell carcinoma), CNS (schizophrenia, epilepsy, dementia, multiple sclerosis) and inflammatory diseases (ankylosing spondylitis and rheumatoid arthritis).
We’ve collected three example papers for you to review, including an interrogation of effect measure interpretation in major general medical journals, a cost systematic review in epilepsy and an RCT systematic review and network meta-analysis (NMA) publication in rheumatoid arthritis.
More papers will follow.
The images below will lead you to a synopsis of the papers and a link to the full version.